News

Sanofi to buy Kiadis

Sanofi to buy Kiadis

The move gives the French drug giant access to Kiadis’ natural killer cell technology platform

New EU approval for GSK’s Zejula

New EU approval for GSK’s Zejula

Zejula is the first PARP inhibitor to be approved as monotherapy in the EU for patients with platinum-responsive advanced ovarian cancer, regardless of biomarker status